Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1839100 metabolism and bioavailability in healthy volunteers
NCT06572111Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 1839100 (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Mass balance and total recovery of [C-14]-radioactivity in urine and feces at 21 days and Area under the concentration-time curve extrapolated to infinity at 21 days. Started Sep 2024; status: terminated.
02
Drugs
BI 1839100
Beyond the preview
Go deeper on NCT06572111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06572111.